There is considerable interest in the development of chemical methods for the precise, site-selective modification of antibodies for therapeutic applications. In this protocol, we describe a strategy for the irreversible and selective modification of cysteine residues on antibodies, using functionalized carbonylacrylic reagents. This protocol is based on a thiol-Michael-type addition of native or engineered cysteine residues to carbonylacrylic reagents equipped with functional compounds such as cytotoxic drugs. This approach is a robust alternative to the conventional maleimide technique; the reaction is irreversible and uses synthetically accessible reagents. Complete conversion to the conjugates, with improved quality and homogeneity, is often achieved using a minimal excess (typically between 5 and 10 equiv.) of the carbonylacrylic reagent. Potential applications of this method cover a broad scope of cysteine-tagged antibodies in various formats (full-length IgGs, nanobodies) for the site-selective incorporation of cytotoxic drugs without loss of antigenbinding affinity. Both the synthesis of the carbonylacrylic reagent armed with a synthetic molecule of interest and the subsequent preparation of the chemically defined, homogeneous antibody conjugate can be achieved within 48 h and can be easily performed by nonspecialists. Importantly, the conjugates formed are stable in human plasma. The use of liquid chromatography-mass spectrometry (LC-MS) analysis is recommended for monitoring the progression of the bioconjugation reactions on protein and antibody substrates with accurate resolution.
Introduction
Protein bioconjugation has been widely used in the design of biologically active conjugates for applications in biology and medicine [1] [2] [3] [4] . Despite substantial progress in this field [5] [6] [7] [8] , there is still considerable interest in the development of efficient methods for site-selective chemical installation of modifications into proteins, especially those that can be applied to the covalent attachment of cytotoxic drugs to antibodies 1, 9, 10 . To date, most approaches for the preparation of antibody-drug conjugates (ADCs) have used methods that typically result in heterogeneous products containing a mixture of species with different drug-to-antibody ratios and, potentially, different pharmacokinetics. Current trends in ADC design are related to achieving site-selective antibody conjugation and a controlled drug-to-antibody ratio while forming products that are stable while in circulation to avoid premature drug release and thus side toxicity.
We have recently reported the design of a new class of Michael-acceptor reagents, carbonylacrylic (caa) derivatives, that undergo very rapid, chemoselective thiol-Michael addition with cysteine residues on proteins 11 . The reaction can proceed to completion even when a single molar equivalent of synthetically accessible reagents is used at low protein concentrations, generating homogeneous conjugates that are fully resistant to degradation in human plasma. The reaction typically results in a homogenous conjugate; most proteins do not have free cysteine residues, and, for most examples, we have engineered the proteins to have a unique cysteine. In examples with multiple cysteines, we have found that all available residues have reacted to form the corresponding thioether. The utility of this reaction has been demonstrated for the labeling of proteins, including antibodies that are available with a free cysteine through large-scale production. The modified proteins (albumin, Annexin-V, C2A domain of synaptotagmin-I (C2Am) and the antibody Thiomab LC-V205C) retained their biological activity after chemical conjugation. Using a fluorescently labeled conjugate of C2Am, which binds to the apoptotic biomarker phosphatidylserine, we were able to selectively image and detect apoptotic cells.
Overview of the procedure
The protocol presented here describes the preparation and use of simple carbonylacrylic acid derivatives to perform cysteine chemoselective and irreversible protein chemical modification. In particular, we exemplify the utility of the method for the construction of antibody conjugates. Antibodies are an important class of biotherapeutics, and their precise chemical modification to generate ADCs bearing a defined number of drugs at specific sites is critical for their therapeutic activity 1, 4, 9 . Taking into account the importance of the conjugation method in generating ADCs with improved therapeutic index 12 , we decided to demonstrate the general utility of carbonylacrylic reagents for ADC construction through selective cysteine modification. The first step involves the facile synthesis of functionalized carbonylacrylic reagents by coupling a commercially available trans-3-benzoylacrylic acid to payloads bearing a free amine handle. The resulting functionalized Michael-acceptor reagent is then used as a substrate for the modification of cysteine-tagged antibodies. Notably, complex structures containing a cleavable linker and a cytotoxic drug are readily coupled by using a few (5-10) molar equivalents of the carbonylacrylic reagent, generating stable and fully functional antibody conjugates.
Applications of the method
Different functional groups can be readily attached to the commercially available carbonylacrylic scaffold using classic amidation conditions of the corresponding carboxylic acid reagent. Many relevant conjugation reagents, such as fluorescent probes, PEG, carbohydrate, DNA and drug derivatives, are commercially available and feature a free reactive amine handle 11, 13 . With the reagent in hand, this simple, irreversible and chemoselective approach can be directly used to modify several antibodies at cysteines that may be either genetically encoded or generated by disulfide reduction. In this protocol, we exemplify the use of the method for the modification of antibodies, including native full-length IgG antibodies (modification at cysteines that result from the reduction of native interchain disulfides), engineered IgGs with genetically encoded additional cysteine residues in the light chain, and smaller recombinant antibody fragments, such as a nanobody. For example, this method was recently used to create a stable nanobody-drug conjugate bearing a thioether-directing palladium-cleavable linker for targeted bioorthogonal drug decaging 13 .
Comparison with other methods and limitations
Cysteine is the residue of choice (over lysine) when modifying proteins because of its low abundance (1.9% for cysteine and 5.9% for lysine) and the high nucleophilicity of its sulfhydryl side chain (pKa = 8.0 for cysteine and 10.5 for lysine) 14 . The most used strategy for cysteine modification on biomolecules utilizes maleimide reagents (Fig. 1a ) 15, 16 . There are, however, a number of limitations of the maleimide strategy that include the need to use a slightly acidic pH to avoid cross-reactivity with lysine residues and the use of excess equivalents to achieve complete conversion. But the main limitation of maleimide conjugation is that the reaction is reversible: the product undergoes retro-Michael addition reactions with biological thiols in plasma, leading to the release of the maleimide scaffold (Fig. 1a) . Some strategies to slow the retro-Michael reaction have been proposed, including the replacement of endocyclic olefin with an exocyclic one 17 . However, the kinetics of the reaction is slower and requires a larger excess of reagent to achieve useful conversions on antibodies. Methods to generate stable ring-opened products by hydrolysis of the thio-succinimidyl conjugate have been described in two steps (Fig. 1b) 18 . Initially, a basic amino group is installed on the maleimide structure by synthetic chemistry or by genetic engineering of the sequence adjacent to cysteine (Fig. 1b) 18 . Hydrolysis of the thio-succinimidyl intermediate is promoted by basic media generating a stable ring-opened structure that does not undergo a retro-Michael addition reaction. Although improved in vivo stability is achieved, the requirement of extensive engineering of antibody substrates or incomplete hydrolysis can reduce conjugation efficiency (Fig. 1b) . By contrast, the present method (Fig. 1c) forms conjugates that are stable in the presence of biological thiols and fully stable in plasma. In addition, the reaction shows complete chemoselectivity and proceeds even at a slightly basic pH, with no side reaction observed at competing nucleophilic amino acids such as lysine. The method has a broad substrate scope and allows the installation of a wide range of synthetic modifications on different protein scaffolds, including antibodies, without disturbing their native antigen-binding properties. The method presented is straightforward and, depending on the reactivity and accessibility of the cysteine residue to be modified, reaction optimization with regard to duration and number of equivalents of the carbonylacrylic reagent may be necessary. A range from 1 to 10 equiv. of the functionalized carbonylacrylic reagent, a temperature of 37°C, and 1-6 h of reaction duration using buffer with pH 7.0-8.0 were found to provide complete conversion to the desired homogeneous antibody conjugates.
Experimental design
Our protocol involves the use of carbonylacrylic reagents for chemoselective and irreversible cysteine bioconjugation. These reagents undergo rapid thiol-Michael addition under biocompatible conditions (aqueous buffer, near to physiological pH and temperature, and <10% (vol/vol) organic solvent) (Fig. 2a ) 11 . We began our study by reacting the simple carbonylacrylic reagent (E)-N-ethyl-4-oxo-4-phenylbut-2-enamide (1) with three different cysteine-tagged antibodies targeting the Her2 antigen: the 2Rb17c nanobody 19 (one engineered, surface-exposed cysteine, Fig. 2b ), trastuzumab (one cysteine residue on the light chain and three on the heavy chain, resulting from inter-chain disulfide reduction, Fig. 2c ), and Thiomab LC-V205C (one engineered cysteine in the light chain, Fig. 2d ) 12 . In the case of the 2Rb17c nanobody, complete conversion (>95%, based on LC-MS analysis) in a 95% yield (based on antibody concentration as determined by Bradford protein assay) was typically obtained using 5-10 equiv. of 1 per cysteine after 2 h at 37°C in sodium phosphate buffer (50 mM NaP i , pH 8.0) in open air (Fig. 2a) . Deconvoluted mass spectra of the site-selectively modified antibodies are shown in Fig. 2b-d and Supplementary Figs. 1-5 , indicating product homogeneity, i.e., the starting material was fully consumed and a new product was formed with a precisely installed modification at the intended cysteine residue. Identical data were obtained for trastuzumab-1 when the reaction was left for 24 h (Supplementary Fig. 6 ). For trastuzumab, a total of eight modifications are installed per antibody as a result of the modification of the cysteines resulting from the reduction of four disulfides. In the cases of conjugation of a high number of synthetic modifications per antibody, and depending on the hydrophobic nature of the synthetic modifications, it may be necessary to incorporate a hydrophilic linker such as PEG into the reagent in order to reduce hydrophobicity and potential aggregation of the final conjugate 20 . In the case of Thiomab LC-V205C, two modifications were detected within the light chain, whereas no modifications occurred within the heavy chain ( Fig. 2d and Supplementary Figs. 3 and 5) . This is probably due to inefficient refolding of the disulfide between the light and heavy chains after antibody production, and because 1 is small, two modifications are introduced into the light chain (Fig. 2d) . This is consistent with our data that showed that when Thiomab LC-V205C is reacted with thiol-specific 5,5′-dithiobis(2-nitrobenzoic acid (Ellman's) reagent, two modifications are detected within the light chain, supporting the presence of two reactive cysteine residues ( Supplementary  Fig. 7 ) 21 . Under identical conditions, NaP i (pH 8.0, 50 mM) and 5 equiv. per cysteine, the reaction of Thiomab LC-V205C with the commercially available N-benzylmaleimide affords <5% of the expected conjugate, which highlights the superior reactivity of carbonylacrylic acid reagents for cysteine bioconjugation as compared with maleimides ( Supplementary Fig. 8 ). In the case of a native full-length IgG such as trastuzumab, and after total disulfide reduction, controlled installation of eight modifications (one in each light chain and three in each heavy chain) was achieved using 5 equiv., of the reagent 1 per cysteine residue (Fig. 2d and Supplementary Figs. 2 and 4) . Modification of the cysteine residues resulting from inter-chain disulfide reduction provides rapid access to sites for modification but limits control over the positioning of the modification and leads to a high payload/antibody ratio. Furthermore, although disulfide reduction followed by conjugation of eight modifications has been shown to generate conjugates that maintained the antibody's binding capacity 22 , there may be cases in which the destruction of these disulfides may lead to loss of structure and biological function.
We next evaluated the stability of the antibodies conjugated with 1 in human plasma. This is important in assessing whether the conjugate can survive the conditions while in circulation and thus avoid premature release of the payload. Stability should be checked for any therapeutic conjugate before biological evaluation. Importantly, we observed that the thioether conjugate formed after the reaction of the sulfhydryl side chain of cysteine with the carbonylacrylic reagent exhibited complete resilience to degradation, remaining intact at 37°C, as demonstrated by LC-MS analysis ( Supplementary Figs. 9-11 ).
It is important to also check that the antibody can still perform its function after conjugation. For the recognition of Her2 receptors displayed on the surface of Her2 + cells, SKBR3 cells were stained with 100 nM of trastuzumab-1 and Thiomab-1 for 1 h, at 4°C and then stained with anti-human IgG Alexa Fluor 647 secondary antibody. The specific binding is illustrated in the histogram FACS plots, in which red curves represent the antibody-conjugate binding, blue curves correspond to the secondary antibody control, and the gray curves represent unstained cells (Fig. 2e,f) . By flow cytometry analysis, we were pleased to confirm that the antibody conjugates retain their specificity toward Her2 + cells. This was also true for trastuzumab, which has been modified at the eight cysteine residues that resulted from prior reduction of the four inter-chain disulfides. These data demonstrate well the mildness of the conjugation process and its potential for the preparation of homogeneous, stable and functional antibody conjugates.
The preparation of two derivatized carbonylacrylic reagents equipped with a drug payload, followed by chemoselective cysteine modification of an antibody of interest, is illustrated in Figs. 3 and 4a,b. The first example, a carbonylacrylic-tagged ValCit-PAB-MMAE derivative (2) featuring the cleavable linker-drug ValCit-PAB-MMAE motif, which is routinely used for the preparation of ADCs, was easily synthesized from H-ValCit-PAB-MMAE and trans-3-benzoylacrylic acid (Fig. 3a and Supplementary Figs. 12-17 ). Drug release from ADCs (e.g., brentuximab vedotin) 23 built using ValCit-PAB-MMAE is mediated by cathepsin-B hydrolysis of the protease-sensitive valine-citrulline (ValCit) dipeptide linker, followed by [1, 6] -fragmentation of p-aminobenzylcarbamate (PAB) 24 . Using the same coupling conditions (N-methyl morpholine and isobutyl chloroformate (IBCF)), a non-cleavable carbonylacrylic drug was prepared from trans-3-benzoylacrylic acid and crizotinib ( Fig. 3b and Supplementary Fig. 18 ). Crizotinib is an ALK tyrosine kinase inhibitor indicated for patients with locally advanced or metastatic non-small-cell lung cancer 25 . These examples illustrate the synthetic accessibility to carbonylacrylic-tagged reagents for cysteine site-selective and irreversible modification from substrates bearing an amine handle.
With the carbonylacrylic-functionalized cleavable linker and drug in hand, we decided to demonstrate the utility of the method by site-selective conjugation of 2 to the engineered cysteine at position 205 in Thiomab. Unexpectedly, we found that the use of one or excess molar equivalents of 2 per cysteine residue did not provide useful conversions to the desired conjugate when the reaction was performed in 50 mM NaP i , pH 8.0 or pH 9.0, after 24 h (Supplementary Figs. 21 and 22) . However, when the ionic strength of the buffer was changed to 20 mM and the pH was slightly lowered to 7.0, efficient conversion to the desired product was observed at 6 h (Fig. 4a,b and Supplementary Fig. 23 ). Unlike the reaction with 1, which resulted in two modifications in the light chain, a single modification was incorporated, which is in accordance with what has been previously described in the literature when modifying Thiomab LV-V205C using maleimide-ValCit-PAB-MMAE 12 . Importantly, no modifications were detected in the heavy chain, as was previously observed for the reaction with 1, which demonstrates the site selectivity of the approach. Finally, we showed that the homogeneous ADC, Thiomab LC-V205C-2, retained the antibody's native binding capacity to the Her2 antigen, as evidenced by flow cytometry analysis in high-Her2-expressing SKBR3 cells (Fig. 4c) .
Next, we applied the optimal conditions found for the modification of the anti-tenascin C fully human antibody F16, which has displayed promising biodistribution results in mouse models of cancer and in patients 26, 27 . The F16 antibody was expressed in engineered human IgG1 format, which contained a single cysteine residue at the light chain for site-selective conjugation, a C-terminal disulfide that connected the heavy chains, and a substitution of an asparagine residue in the VL domain with a glutamine that abolished N-linked glycosylation 28 . When F16 antibody (5 μM) was treated with 5 equiv. per cysteine of caa-ValCit-PAB-MMAE (2), >95% conversion to an homogeneous conjugate with a single modification within the light chain was observed using LC-MS after 6h (Fig. 5a,b, Supplementary Fig. 24 ). No modifications were detected in the heavy chain of the antibody. Using the same conditions, the treatment of F16 antibody with 5 equiv. per cysteine of caacrizotinib (3) furnished the desired conjugate, with complete conversion (Fig. 5a,c, Supplementary  Fig. 25 ). These data further highlight the robustness of our method for the site-selective conjugation of drugs to tumor-homing antibodies.
Reaction scale
The procedure can be performed on a variety of scales, with our laboratory having successfully performed the conjugation on individual protein and antibody samples ranging from 10 to 200 μM. In all cases, scaling up the reaction resulted in identical efficiency as monitored by LC-MS analysis. Of note, when scaling up the reaction to high protein concentrations, the amount of organic solvent used should be adjusted by increasing its total amount up to 10% to avoid precipitation of the reagent.
Reaction monitoring
The use of LC-MS is recommended for monitoring the progression of the bioconjugation reactions on protein and antibody substrates with accurate resolution. 
Materials Biological materials
• SKBR3 cells (human breast adenocarcinoma cell line; ATCC, cat. no. ATCC HTB-30) c CAUTION The cell lines used in your research should be regularly checked to ensure that they are authentic and that they are not infected with mycoplasma.
Reagents
! CAUTION Reagents used in the Procedure are potentially dangerous, and appropriate care should be taken during their manipulation. The reaction of carbonylacrylic acid with a cytotoxic payload should be always performed with maximum care in a fume hood. The solid and liquid waste products generated should be disposed of appropriately, as defined locally. c CRITICAL Use all commercially available reagents as received unless otherwise noted.
• Monomethyl auristatin E (MMAE; Carbosynth, cat. no. FM63498) ! CAUTION MMAE is a highly toxic compound, and appropriate care should be taken during manipulation, including the wearing of personal protective equipment and conduction of the reaction in a fume hood. • Analytical HPLC system for peptide/caa-ValCit-PAB-MMAE (2) analysis (Waters 1525 system equipped with a Phenomenex Luna C18(2) column (5 μm, 250 × 4.6 mm) and a dual absorbance detector) • MS-ESI system for peptide/caa-ValCit-PAB-MMAE (2) analysis (Waters Acquity UPLC system, equipped with a Bruker MicrOTOF-Q detector) • MALDI-TOF system for peptide/caa-ValCit-PAB-MMAE (2) analysis (microflex, Bruker)
• MS-ESI system for protein/antibody analysis (Water Acquity UPLC system, equipped with a single quadrupole mass detector 2) • Lyophilizer (VirTis; Sp Scientific) • Slide-A-Lyzer dialysis cassettes (10 K MWCO, 3 mL; Thermo Scientific, cat. no. 66380) • Zeba Spin desalting column (7 K MWCO, 0.5 mL; Thermo Scientific, cat. no. 89882) 
Reagent setup

Antibody reaction buffer
The reaction buffer is 20 or 50 mM sodium phosphate buffer (NaP i ) at pH 7.0 or 8.0. For 1, use 20 mM, pH 8.0; for 2 or 3, use 50 mM, pH 7.0. Once prepared, this buffer can be stored and used for up to 1 month at room temperature (15-25°C).
Caa-ValCit-PAB-MMAE (2) stock solution
The stock solution of this reagent (2.34 mM) can be prepared in N,N-dimethylformamide anhydrous (DMF) on the day of the experiment and stored at −20°C for up to 1 week. For improved efficiency of the conjugation, it is advised to use freshly prepared solutions. Mass spectrometry for peptide/caa-ValCit-PAB-MMAE analysis MS analysis is performed using a Waters Acquity system, with parameters as displayed in the table below.
Method parameter Value
Capillary voltage 4,500 V End plate offset −500 V Nitrogen is used as the desolvation gas and nebulizer at a total flow of 7.0 L/min. Exact mass spectra are recorded using sodium formate as calibrator. Mass spectrometry for protein/antibody analysis MS analysis is performed using a Waters Acquity system, with parameters as displayed in the table below.
Capillary voltage 3,000 V Cone 20 V Desolvation temperature 400°C
Nitrogen is used as the desolvation gas and nebulizer at a total flow of 8.0 L/h. Exact mass spectra are recorded using sodium formate as calibrator.
Cell analyzer for binding affinity detection Flow cytometry analysis is performed using an LSR Fortessa cell analyzer from BD Biosciences. To detect antibody binding to SKBR3 cells, the equipment is set up with a 640-nm laser and a 670/14-nm band-pass filter (combination used for APC detection).
Procedure
Synthesis of functionalized carbonylacrylic reagent (2) • Timing 4 h c CRITICAL In these steps, we describe how to synthesize caa-ValCit-PAB-MMAE (2) . For the synthesis of caa-crizotinib (3), see the Supplementary Methods. 1 Prepare the carboxylic acid solution. In a 10-mL round-bottom flask, dissolve 30 mg of trans-3-benzoylacrylic acid (5 equiv.) in 1 mL of dry DMF and cool the resulting solution at −10°C in an acetone bath cooled with a CryoCool cooler. c CRITICAL STEP Cooling can also be achieved using an NaCl ice bath; the CryoCool system is, however, better suited to maintaining the low temperature. c CRITICAL STEP The product must be immediately lyophilized after purification to avoid degradation. j PAUSE POINT The product can be stored as a solid at −20°C for 4 months.
Procedure for antibody modification • Timing 20-22 h
8 Prepare a stock solution of caa-ValCit-PAB-MMAE (2) in an Eppendorf tube. Dissolve the desired functionalized reagent (3 mg) in 1,000 μL of DMF to a concentration of 2.3 mM. Vortex for 10 s, if necessary, to obtain a homogeneous solution. j PAUSE POINT The caa stock solution in DMF was found to be stable for~1 week at −20°C, depending on the structure. Caa functionalized reagents with fluorescent probes tend to be less stable than caa reagents bearing PEG units or drugs. 9 Prepare a 20 mM solution of NaP i at pH 7.0. c CRITICAL STEP 20 and 50 mM solutions of NaP i at pH 8.0 work for most antibodies and caa reagents tested. In the case of modification using caa-ValCit-PAB-MMAE (2), the use of NaP i (20 mM, pH 7.0) was critical to achieving complete conversion. When labeling high-molecular weight proteins, we advise trying a lower pH and lower-ionic-strength buffer. 10 In an Eppendorf tube, prepare the reaction medium by dissolving 12.5 μL of the antibody stock solution (Thiomab LC-V205C at an initial concentration of 80 μM) in 23.5 μL of NaP i (20 mM, pH 7.0). Vortex the mixture for 10 s until all materials are dissolved. 11 Initiate the reaction by pipetting 4.3 μL (10 equiv.) of the caa-ValCit-PAB-MMAE (2) stock solution directly into the Eppendorf tube containing the antibody. Vortex the tube for 10 s. Total volume = 40 μL; final antibody concentration = 25 μM. 12 Incubate the reaction mixture at 37°C for 6 h (shaking at 600 r.p.m.). 13 Analyze the reaction outcome by LC-MS. 10-μL aliquots of antibody reaction mixture can be directly used for LC-MS analysis. The calculated mass for the light chain is 24,721 Da, and the observed mass was 24,721 Da (Fig. 4) . No modifications are expected on the heavy chain. ? TROUBLESHOOTING 14 (Optional) For further applications, reagent excess can be removed by loading the sample onto a Zeba Spin desalting column pre-equilibrated with the desired storage buffer (20 mM NaP i , pH 7.0 or 50 mM NaP i , pH 8.0). Perform the purification, eluting the sample by following the manufacturer's instructions. Check the sample concentration after this procedure, using, for example, the Bradford protein assay. In this protocol, when the reaction was scaled up for in vitro and in vivo studies, the conjugate was further dialyzed (Slide-A-Lyzer Dialysis Cassettes, 10-K MWCO, 3 mL) against three changes of 20 mM NaP i (pH 7.0) at room temperature for 12 h. j PAUSE POINT The antibody conjugate can be stored at −20°C for up to 6 months. 
Troubleshooting
Troubleshooting advice can be found in Table 1 .
Timing
Steps 1-4, preparation of caa-ValCit-PAB-MMAE (2): 2 h Steps 5-7, analysis and purification of reaction mixture: 2 h Steps 8 and 9, preparation of stock solution of caa and NaP i : 30 min Steps 10 and 11, preparation of antibody substrate solution: 30 min Adjust the proportion of DMF. The ratio of DMF/ NaP i should be no more than 1:9. In the protocol described, 1% (vol/vol) DMF was used, but identical results can be obtained in a range of 1-10% DMF No or partial conversion to the desired product Step 12, incubation of reaction: variable, 6-8 h depending on scale Steps 13 and 14, analysis and purification of reaction mixture: 13 h
Step 15 
Anticipated results
Full procedures and characterization data can be found in the Supplementary Material of this protocol and also in the Supporting Information in Bernardim and co-workers 8 . Following the procedure described for the activation and amidation of trans-3-benzoylacrylic acid, the carbonylacrylic reagent equipped with the synthetic modification of interest should be achieved in moderate to good yields (~40-80%). If impurities are detected, the activation step may have partially failed due to lack of temperature control. By using the obtained functionalized carbonylacrylic reagent and following the described bioconjugation procedure, site-selective, homogeneous antibodies should be formed by LC-MS as single species with a >95% conversion rate and 80-95% yield of the desired product, as judged by calculation from peak intensities in the deconvoluted spectrum and calculation of non-modified versus modified antibody concentration using the Bradford protein assay. In the case of Thiomab, it should be noted that two modifications were detected in the light chain when using carbonylacrylic reagents with low-molecular weight, whereas a single modification was detected when using the larger caa-ValCit-PAB-MMAE (2) reagent. No peaks below the expected starting material mass should be observed; if such peaks are observed, follow Table 1 to adjust the concentration of DFM in solution (up to 10% (vol/vol)) or the buffer ionic strength (20 or 50 mM) and pH (7.0 or 8.0).
